222 related articles for article (PubMed ID: 31444628)
1.
van Steenbergen TRF; Smits M; Scheenen TWJ; van Oort IM; Nagarajah J; Rovers MM; Mehra N; Fütterer JJ
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):147-154. PubMed ID: 31444628
[TBL] [Abstract][Full Text] [Related]
2.
de Jong AC; Smits M; van Riet J; Fütterer JJ; Brabander T; Hamberg P; van Oort IM; de Wit R; Lolkema MP; Mehra N; Segbers M; van der Veldt AAM
J Nucl Med; 2020 Nov; 61(11):1607-1614. PubMed ID: 32169916
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Prospective comparison of
Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous Lung Tumor Biopsy Under CBCT Guidance with PET-CT Fusion Imaging: Preliminary Experience.
Floridi C; Carnevale A; Fumarola EM; Schampaert S; Fontana F; De Palma D; Del Sole A; Giganti M; Carrafiello G
Cardiovasc Intervent Radiol; 2019 Nov; 42(11):1644-1648. PubMed ID: 31218410
[TBL] [Abstract][Full Text] [Related]
6.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
8. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
[TBL] [Abstract][Full Text] [Related]
9. Diffuse bone metastases on (68)Ga-PSMA PET-CT in a patient with prostate cancer and normal bone scan.
Lavalaye J; Kaldeway P; van Melick HH
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1563-4. PubMed ID: 27121692
[TBL] [Abstract][Full Text] [Related]
10. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
11. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
12.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
13. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
14. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer.
McKay RR; Zukotynski KA; Werner L; Voznesensky O; Wu JS; Smith SE; Jiang Z; Melnick K; Yuan X; Kantoff PW; Montgomery B; Balk SP; Taplin ME
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):325-31. PubMed ID: 25091040
[TBL] [Abstract][Full Text] [Related]
15.
Liu C; Liu T; Zhang Z; Zhang N; Du P; Yang Y; Liu Y; Yu W; Li N; Gorin MA; Rowe SP; Zhu H; Yan K; Yang Z
J Nucl Med; 2020 Sep; 61(9):1314-1319. PubMed ID: 32034111
[TBL] [Abstract][Full Text] [Related]
16. Exploring New Multimodal Quantitative Imaging Indices for the Assessment of Osseous Tumor Burden in Prostate Cancer Using
Bieth M; Krönke M; Tauber R; Dahlbender M; Retz M; Nekolla SG; Menze B; Maurer T; Eiber M; Schwaiger M
J Nucl Med; 2017 Oct; 58(10):1632-1637. PubMed ID: 28546330
[TBL] [Abstract][Full Text] [Related]
17. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
[TBL] [Abstract][Full Text] [Related]
18.
Hruby G; Eade T; Emmett L; Ho B; Hsiao E; Schembri G; Guo L; Kwong C; Hunter J; Byrne K; Kneebone A
Asia Pac J Clin Oncol; 2018 Aug; 14(4):343-346. PubMed ID: 29663686
[TBL] [Abstract][Full Text] [Related]
19. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
Donners R; Figueiredo I; Westaby D; Koh DM; Tunariu N; Carreira S; de Bono JS; Fotiadis N
Cancer Imaging; 2023 Dec; 23(1):121. PubMed ID: 38102655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]